MSL
ATXI

Mackay Shields LLC’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Mackay Shields LLC’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22
Closed -$272K – 1569
2020
Q2 		$272K Buy
+22
New +$248K ﹤0.01% 1317

Other funds holding ATXI

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mackay Shields LLC's ATXI Position: Q3 2020 in Review

Mackay Shields LLC sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q3 2020, closing a stake of 22 shares — an estimated $272K sold.

Mackay Shields LLC first reported a position in ATXI in Q2 2020 and held it in 1 quarter. The position peaked at $272K in Q2 2020. 31 funds tracked by Wall St. Rank hold ATXI as of Q3 2020.

  • Mackay Shields LLC reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Mackay Shields LLC sold 22 Avenue Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $272K.
  • Mackay Shields LLC first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Mackay Shields LLC's Avenue Therapeutics, Inc. Common Stock position peaked at $272K in Q2 2020.
  • 31 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.